HR
UTHR icon

Hayden Royal’s United Therapeutics UTHR Stock Holding History

Hayden Royal’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$174K Buy
+806
New +$158K 0.41% 90

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Hayden Royal's UTHR Position: Q4 2021 in Review

Hayden Royal opened a new position in United Therapeutics (UTHR) in Q4 2021: 806 shares worth $174K. The stake represents 0.41% of the portfolio and ranks #90 among its holdings.

416 funds tracked by Wall St. Rank hold UTHR as of Q4 2021.

  • Hayden Royal held 806 shares of United Therapeutics worth $174K as of Q4 2021.
  • United Therapeutics was a new Hayden Royal position in Q4 2021.
  • United Therapeutics made up 0.41% of Hayden Royal's portfolio in Q4 2021, its #90 holding.
  • 416 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2021.

Based on Hayden Royal's 13F filing for Q4 2021, filed 7 Feb 2022.